Towards Healthcare Research & Consulting

In-Vitro and In-Vivo Micro Electrode Array Corporate Milestones

Date : 05 May 2026

Companies Offerings in the In-Vitro And In-Vivo Micro Electrode Array Market

In-Vitro And In-Vivo Micro Electrode Array Market Companies are Axion BioSystems, Inc., MaxWell Biosystems AG, 3Brain AG, Blackrock Neurotech, Multi Channel Systems MCS GmbH, Med64 (Alpha MED Scientific), Plexon Inc.

Companies Description
Axion BioSystems, Inc. Its offerings cover in-vitro microelectrode array (MEA) solutions focused on its Maestro MEA platform. 
MaxWell Biosystems AG They are highly emphasizing in-vitro high-density microelectrode array (HD-MEA) technology.
3Brain AG This firm specialises in high-density microelectrode arrays relied on CMOS (complementary metal-oxide-semiconductor) technology.
Blackrock Neurotech A company offers Utah Array technology, which is ideal for both in-vivo & in-vitro research applications.
Multi Channel Systems MCS GmbH This leader facilitates a comprehensive suite of microelectrode array (MEA) solutions for both in vitro & in vivo electrophysiology.
Med64 (Alpha MED Scientific) Its brand highly provides solutions for extracellular electrophysiology in cell cultures & tissue slices.
Plexon Inc. Its offerings cover specialized 3D arrays, active CMOS probes, & unified stimulation systems.
NeuroNexus Technologies, Inc.  This firm provides solutions from high-density penetrating silicon probes to flexible surface grids & specialized 3D arrays.
Tucker-Davis Technologies, Inc. A player focuses on comprehensive hardware & software approaches for microelectrode array (MEA) interfacing.
Harvard Bioscience Inc. Their offerings feature cutting-edge Mesh MEA technology for organoids, with traditional planar and 3D arrays.

What are the Recent Developments in the In-Vitro And In-Vivo Micro Electrode Array Market?

  • In April 2026, Neuvotion, Inc. announced the rollout of NeuStim as part of its AI-guided brain-body interface platform for recovery after stroke or injury.
  • In February 2026, Axion BioSystems acquired the intellectual property and assets of CytoTronics, Inc to explore high-density (HD) electrode array technology for disease research and drug discovery.

Market Growth

The global in-vitro and in-vivo micro electrode array market size was estimated at USD 1.35 billion in 2025 and is predicted to increase from USD 1.47 billion in 2026 to approximately USD 3.17 billion by 2035, expanding at a CAGR of 8.9% from 2026 to 2035.

In-Vitro And In-Vivo Micro Electrode Array Market Size is USD 1.47 Billion in 2026.